Cardinal Health Inc.

Cardinal Health is a healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. The company's segments include: Pharmaceutical and Medical. The company's Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. The company's Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets.
  • TickerCAH
  • ISINUS14149Y1082
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Cardinal Health, Inc. - March 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Cardinal Health, Inc.: Sale of Cordis business is credit positive, enhancing liquidity while exiting a challenging business

Cardinal Health's sale of its Cordis business is credit positive as it will generate meaningful cash proceeds ahead of a potential opioids settlement and reduce longer-term investment needs.

Moody's announces completion of a periodic review of ratings of Cardinal Health, Inc.

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Cardinal Health, Inc.. Global Credit Research- 01 Mar 2021. New York, March 01, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Cardinal Health, Inc. and other ratings that are associated with the same analytical unit.

Cardinal Health, Inc. - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Cardinal Health Inc: 1 director sold

A director at Cardinal Health Inc sold 3,291 shares at 51.980USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of b...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of names in the Communications Sector are showing signs of leadership. (ex. GLUU, TWTR, GOOGL, NYT, and NWSA) • Consumer Discretionary continues to have a number of attractive names technically. (ex. TPR, LGIH, DHI, VSTO, RGR, PENN, SGMS, BYD, BJRI, BKE, EBAY, SIG, HAIN, and ENR ) • A number of Financial Sector names appear to be perking up. (ex. JHG, INTL, EVR, GHL, ARR, and CINF)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

• A number of Consumer Cyclical names continue to indicate leadership. (ex. THO, WGO, CROX, WLH, LEN, KBH, PZZA, TXRH, SCVL, GCO, and RH) • The Healthcare Sector has a number of attractive names developing major bases and staging RS reversals. (ex. CAH, HSIC, ITGR, ABT, MLAB, RMD, SYK, MD, RDNT, TRHC, CNC, WCG, RGNX, BEO, and SYNH) • The Technology Sector continues to be long-term leadership. Many issues are extended and we would suggest taking opportunity of any weakness. (ex. TER, AMAT, SYNA, INTC, AVGO, INTU, LPSN, CTXS, ADP, EXLS, PRSP, and FN)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Many Consumer Discretionary names are staging reversals or developing bullish bases. (ex. CPRI, CRI, OXM, PENN, LOCO, PZZA, DPZ, WW, CHS, ZUMZ, and GES) • The Healthcare Sector has a significant number of names reversing downtrend, breaking out of bases, and in uptrends (ex. CAH, TCMD, THC, SEM, MGLN, RGEN, REGN, MEDP, PRAH, and BMY) • Semis and Semi suppliers continue to develop positively. (ex. UCTT, ICHR, FORM, AEIS, and BRKS)

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Cardinal Health Inc: 1 director sold

A director at Cardinal Health Inc sold 3,291 shares at 51.980USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of b...

Valens Research

Valens Equity Insights and Inflections - 2021 01 19

ASGN is currently valued like it is a struggling staffing company, not that it is focused on staffing in some of the tightest labor markets right now in the midst of the At-Home world and the digitization of business. Markets are expecting UAFRS-based (Uniform) ROA (ROA') to decline by almost half, to lows not seen since emerging from the Great Recession in 2011, with slower growth for the company too. The market is viewing ASGN as a hyper cyclical staffing business, when, thanks to its positioning in areas like AI, machine learning, cloud, cybersecurity, and other tech focused areas, they ar...

Valens Research

CAH - Embedded Expectations Analysis - 2021 01 13

Cardinal Health, Inc. (CAH:USA) currently trades near historical lows relative to UAFRS-based (Uniform) earnings, with a 14.0x Uniform P/E. At these levels, the market has expectations for profitability to remain weak, and management may have concerns about COVID-19 vaccine distribution, cost reduction efforts, and at-Home solutions growth Specifically, management may lack confidence in their ability to sustain their at-Home solutions sales growth, and they may be concerned about the lack of aggressive cost reduction actions taken across their manufacturing facilities. In addition, they may b...

MarketLine Department

Allergan plc - Strategy, SWOT and Corporate Finance Report

Summary Allergan plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Allergan plc (Allergan or 'the company') is a pharmaceutical company that develops, manufactures and markets branded pharmaceutical products, biologic, device, surgical and regenerative medicine products. The company offers products in various therapeutic areas, including central nervous system...

MarketLine Department

MediPal Holdings Corp - Strategy, SWOT and Corporate Finance Report

Summary MediPal Holdings Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights MediPal Holdings Corporation (MediPal) controls, administers and supports the operating activities of its group companies which are primarily engaged in the wholesale distribution of prescription pharmaceutical products, over-the-counter (OTC) pharmaceuticals, animal health products, c...

MarketLine Department

McKesson Corporation - Strategy, SWOT and Corporate Finance Report

Summary McKesson Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights McKesson Corporation (McKesson or 'the company') distributes medicines, and provides healthcare services, and information technology solutions. It provides solutions and services to pharmacies, hospitals, pharmaceutical manufacturers, physicians, payers and patients. It distributes gene...

Cardinal Health, Inc. - March 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Cardinal Health, Inc.: Sale of Cordis business is credit positive, enhancing liquidity while exiting a challenging business

Cardinal Health's sale of its Cordis business is credit positive as it will generate meaningful cash proceeds ahead of a potential opioids settlement and reduce longer-term investment needs.

Moody's announces completion of a periodic review of ratings of Cardinal Health, Inc.

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Cardinal Health, Inc.. Global Credit Research- 01 Mar 2021. New York, March 01, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Cardinal Health, Inc. and other ratings that are associated with the same analytical unit.

Cardinal Health, Inc. - December 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Cardinal Health, Inc.: Update to credit analysis

Our credit view of Cardinal Health, reflecting its solid cash flow and its willingness to accelerate debt repayment in order to improve credit metrics, offset by its very low margins.

With a more favourable environment, CARDINAL HEALTH improves to Slightly Positive

CARDINAL HEALTH (US), a company active in the Drug Retailers industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 2 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date February 5, 2021, the closing price was USD 54.26 and its potential was estimated at USD 65.09.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch